News

Acer Therapeutics Forms Scientific Advisory Board

Inaugural team of experts to provide valuable insights and guidance on NDA filing of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome, and pivotal clinical studies of ACER-001 in MSUD and UCD CAMBRIDGE, Mass.,...

read more

Acer Therapeutics Closes $8.15 Million Series B Financing

Financing will support the regulatory filing for the company’s lead product, VASEBRA™, for the treatment of Vascular Ehlers - Danlos Syndrome, as well as pivotal clinical studies for ACER-001 in MSUD and UCD CAMBRIDGE, MA, May 9, 2016 – Acer Therapeutics Inc., a...

read more

News

Acer Therapeutics Forms Scientific Advisory Board

Inaugural team of experts to provide valuable insights and guidance on NDA filing of the company’s lead product, VASEBRA™ (celiprolol), for the treatment of vascular Ehlers-Danlos Syndrome, and pivotal clinical studies of ACER-001 in MSUD and UCD CAMBRIDGE, Mass.,...

read more

Acer Therapeutics Closes $8.15 Million Series B Financing

Financing will support the regulatory filing for the company’s lead product, VASEBRA™, for the treatment of Vascular Ehlers - Danlos Syndrome, as well as pivotal clinical studies for ACER-001 in MSUD and UCD CAMBRIDGE, MA, May 9, 2016 – Acer Therapeutics Inc., a...

read more